KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Depreciation & Amortization (CF) (2016 - 2025)

Cvs Health (CVS) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.1 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 2.33% year-over-year to $1.1 billion, compared with a TTM value of $3.5 billion through Dec 2025, down 24.76%, and an annual FY2024 reading of $4.6 billion, up 5.29% over the prior year.
  • Depreciation & Amortization (CF) was $1.1 billion for Q3 2025 at Cvs Health, down from $1.2 billion in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.2 billion in Q2 2025 and bottomed at $1.0 billion in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) fell 6.84% in 2022, then increased 13.69% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $1.1 billion in 2021, then dropped by 0.64% to $1.1 billion in 2022, then rose by 4.81% to $1.1 billion in 2023, then rose by 1.15% to $1.1 billion in 2024, then decreased by 1.13% to $1.1 billion in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for CVS at $1.1 billion in Q3 2025, $1.2 billion in Q2 2025, and $1.2 billion in Q1 2025.